Morphine: Nursing Drug Guide, Respiratory Depression & NCLEX Review
Morphine sulfate can cause fatal respiratory depression—especially after dose increases, with benzodiazepines, or when IV doses are given too quickly. Nurses must verify mg versus mL, match vial concentration to the order, and assess ventilation before every dose.
Morphine sulfate can cause serious, life-threatening, or fatal respiratory depression, especially during initiation or after a dose increase. IV morphine has a delayed maximum CNS effect (about 30 minutes)—rapid administration may overdose the patient before sedation is recognized. Concomitant benzodiazepines, other CNS depressants, or alcohol may cause coma and death. Highest-risk patients include those with COPD, sleep apnea, the elderly, and the debilitated. Have naloxone and resuscitation equipment available per labeling; assess respiratory rate, sedation, and oxygenation before every dose.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every morphine dose, assess respiratory rate, oxygen saturation, and arousability—and confirm the correct mg dose, mL volume, and vial concentration. An acceptable pain score never overrides inadequate ventilation.
Most common brand names
Morphine is available as immediate-release and extended-release oral products, rectal suppositories, and multiple injectable concentrations. Always verify the specific formulation, route, and concentration on the MAR—not just the word “morphine.”
Common names include MS Contin and Kadian (oral extended-release), Roxanol (oral solution), Duramorph and Astramorph (injection), and numerous generic morphine sulfate products. Injectable concentrations for morphine sulfate injection include 2, 4, 8, 10, and 15 mg/mL per reviewed labeling—dosing errors from mg versus mL or wrong concentration can be fatal.
Why we give it — Indications
Morphine sulfate is an opioid agonist indicated for pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nurses encounter morphine across postoperative units, palliative care, oncology, and monitored acute-care settings where ventilation can be observed and reversal agents are accessible.
| Use | Detail |
|---|---|
| Moderate to severe pain | Management of pain severe enough to require an opioid analgesic when non-opioid options are insufficient—many acute pain episodes require only a few days of opioid therapy per labeling. |
| Limitations of use | Reserve morphine for patients in whom lower doses are insufficient and expected benefits clearly outweigh substantial risks of addiction, abuse, misuse, and respiratory depression. Use the lowest effective dose for the shortest duration consistent with treatment goals. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Morphine binds mu-opioid receptors in the central nervous system, producing analgesia and dose-related respiratory depression by reducing brain-stem responsiveness to carbon dioxide. Carbon dioxide retention from opioid-induced respiratory depression can further increase sedation—a reinforcing risk spiral nurses must recognize early. Concurrent benzodiazepines, sedative-hypnotics, and other opioids synergistically increase fatal respiratory depression per labeling.
Dosing overview
Dosing must be individualized and titrated to effect with continuous respiratory monitoring. The table below reflects morphine sulfate injection labeling; oral immediate-release and extended-release products have separate prescribing information—verify the ordered formulation.
Missed dose: Not specified in the reviewed injection labeling for scheduled regimens. For PRN orders, do not double doses; reassess pain and respiratory status before the next dose and verify cumulative opioid exposure.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Peak CNS effect (IV) | Delay of maximum CNS effect approximately 30 minutes after IV administration per labeling | Rapid IV push may overdose before sedation is apparent—administer slowly and observe longer than immediate-onset drugs |
| Onset / duration (oral) | Not specified in the reviewed injection labeling | Use oral product prescribing information; reassess sedation and RR on a schedule matched to route |
| Half-life | Not specified in the reviewed injection labeling nursing summary | Effects may persist through overlapping PRN intervals—count cumulative doses |
| Metabolism | Hepatic; active metabolite morphine-6-glucuronide accumulates in renal impairment per pharmacology references | Renal impairment increases toxicity risk—coordinate dose with prescriber/pharmacist |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm naloxone injection and resuscitative equipment are immediately available per labeling, especially when initiating therapy
- Review baseline respiratory status, COPD, sleep apnea, obesity hypoventilation, renal function, and concurrent CNS depressants on the MAR
- Perform medication reconciliation for cumulative opioid and sedative exposure; verify mg dose, mL volume, and vial concentration (mg/mL)
- Screen for MAOI use within the last 14 days; confirm no known or suspected gastrointestinal obstruction
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine (e.g., anaphylaxis)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Benzodiazepines and other CNS depressants | Profound sedation, respiratory depression, coma, and death per boxed warning | Reserve concomitant use only when alternatives are inadequate; use lowest doses and shortest duration; hold morphine if excessive sedation or bradypnea develops |
| MAOIs | May potentiate morphine effects including respiratory depression and confusion | Do not give morphine with MAOIs or within 14 days of stopping an MAOI |
| Mixed agonist-antagonists (e.g., buprenorphine) | May reduce analgesia or precipitate withdrawal; respiratory effects unpredictable | Coordinate with prescriber/pharmacy before co-administration; monitor ventilation |
| Other opioids | Additive respiratory depression and sedation | Calculate total opioid equivalents in 24 hours; clarify orders before stacking agents |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Morphine sulfate injection is for intravenous administration per reviewed Hospira labeling (Carpuject and NexJect systems). Other products may be labeled for intramuscular, oral, or rectal use—never assume interchangeability. Morphine is a Schedule II controlled substance—follow institutional controlled-substance and IV medication administration policies.
- Administer IV morphine slowly; labeling warns that rapid administration may result in overdosing because maximum CNS effect is delayed
- Independent double-check mg dose, mL volume, and concentration; avoid confusion between 4 mg/mL and 10 mg/mL vials
- Use high-alert medication administration double-check steps for every dose
- Document time, dose, route, indication, pre- and post-administration respiratory assessment, and double-check participants
Labeling emphasizes that dosing errors can result from confusion between mg and mL and between morphine injections of different concentrations. A 4 mg order drawn from a 10 mg/mL vial without calculation verification can deliver a lethal overdose. Program smart pumps with concentration limits when available.
Expected therapeutic response
- Decrease in pain score on standardized pain assessment without excessive sedation
- Respiratory rate and depth remain within prescriber or protocol parameters; patient remains easily arousable
- SpO2 stable on baseline oxygen therapy; no new bradypnea or shallow breathing pattern
Red flags — Stop and act
Respiratory depression may progress from subtle sedation to apnea—especially within 30 minutes after IV morphine when staff assume the dose was “small.” Escalate immediately.
- Respiratory rate below institutional threshold, shallow respirations, or absent effort (apnea)
- SpO2 decline or new difficulty breathing despite supplemental oxygen
- Marked excessive sleepiness, inability to arouse, or confusion with somnolence
- Severe hypotension, bradycardia, or circulatory depression (labeling lists serious cardiovascular adverse reactions)
- Any suspicion of opioid overdose—initiate airway support and antagonist protocol per facility policy
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Respiratory depression, apnea | Most serious; may be fatal | Stop opioid, support airway, administer antagonist per protocol, continuous monitoring until spontaneous respiration reliably re-established |
| Sedation, dizziness, lightheadedness | Frequently observed per labeling | Monitor sedation scale and RR; hold additional doses if oversedated |
| Nausea, vomiting | Common | Supportive care; protect airway if sedated |
| Constipation | Common opioid effect | Proactive bowel regimen per protocol; teach prevention |
| Hypotension, circulatory depression | Serious when reported | Monitor hemodynamics; avoid in circulatory shock per labeling |
| Hypersensitivity / anaphylactoid reactions | Rare with IV morphine | Stop permanently; treat per severe allergy protocol if present |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose manifests primarily as respiratory depression ranging from reduced rate to apnea. Circulatory depression, respiratory arrest, shock, and cardiac arrest are also listed among the most serious adverse reactions in reviewed labeling.
Early signs
- Increasing sedation, miosis, declining respiratory rate or depth
- Hypoxemia on pulse oximetry despite supplemental oxygen
- Carbon dioxide retention worsening sedation (narcotic effect per labeling)
Antidote
Opioid antagonists such as naloxone are specific antidotes to respiratory depression resulting from morphine overdose per reviewed prescribing information. For clinically significant respiratory or circulatory depression, administer an opioid antagonist while supporting ventilation. Continue monitoring and repeat antagonist doses as directed because reversal duration may be shorter than morphine action—especially in physically dependent patients, where titrated reversal avoids precipitated withdrawal while restoring ventilation.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Maintain airway and ventilation while awaiting specialist input.
Look-alike / sound-alike and error prevention
- Morphine vs hydromorphone (Dilaudid)—different potency; verify generic name and concentration on vial and MAR
- mg vs mL—calculate volume from ordered mg and vial concentration; never assume 1 mL equals 1 mg
- 4 mg/mL vs 10 mg/mL vs 15 mg/mL—independent double-check before administration
- Oral ER vs immediate-release vs injection—never substitute formulations without prescriber and pharmacy review
- Morphine vs magnesium—verify drug name on high-alert workflows when handwriting or verbal orders are used
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| 30-minute IV watch | Stay vigilant for delayed peak CNS effect after IV morphine—do not leave for another task immediately after a bolus if policy requires observation. |
| PCA pumps | Verify concentration in pump library matches pharmacy-prepared bag; teach patients not to let others press the button. |
| Bowel regimen | Start prophylactic constipation measures with ongoing opioid therapy unless contraindicated. |
| Renal patients | Active metabolites accumulate—lower doses and longer monitoring intervals may be needed; consult pharmacy. |
| Commonly missed | Scheduled benzodiazepine on MAR plus PRN morphine without reassessment of cumulative sedation. |
| Ask pharmacy when | Unclear mg/mL calculation, opioid rotation, partial antagonist response, or recurrent depression after naloxone. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Elderly, cachectic, debilitated | Life-threatening respiratory depression more likely because of altered pharmacokinetics or clearance—start at low end of dosing range and monitor closely per labeling. |
| COPD, cor pulmonale, decreased respiratory reserve | Even recommended doses may decrease respiratory drive including apnea—continuous SpO2 monitoring and lower starting doses. |
| Concurrent CNS depressants | Reserve concomitant benzodiazepines or sedatives only when alternatives inadequate; profound respiratory depression risk. |
| Pregnancy / labor | Extended opioid use can cause neonatal opioid withdrawal syndrome; labeling does not recommend morphine sulfate injection during and immediately prior to labor when shorter-acting analgesics are more appropriate. |
| Breastfeeding | Morphine present in breast milk; insufficient data on breastfed infant effects for injection product—monitor infant for sedation and respiratory depression per LactMed when mothers receive morphine. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory rate, depth, and pattern; sedation level; blood pressure and heart rate per protocol
- Continuous or frequent pulse oximetry during titration and for at least 30 minutes after IV bolus when policy requires
- Pain scores alongside ventilation—analgesia without adequate respiration is not a safe outcome
- Bowel function, urine output, and mental status on ongoing therapy
Document
- Dose (mg and mL), concentration, route, time, indication, pre/post respiratory assessment, and independent double-check
- Cumulative opioid and sedative exposure at handoff; antagonist doses and response if given
- Patient education on reporting somnolence, breathing difficulty, and constipation
Patient teaching
- Morphine can slow breathing to a dangerous level—report unusual sleepiness, slow or shallow breathing, or difficulty staying awake
- Do not take other sedatives, alcohol, or extra pain medicine unless the prescriber approves—combined drugs increase overdose risk
- Prevent constipation with fluids, fiber, and prescribed laxatives as directed
- Seek urgent help for severe breathing difficulty or inability to arouse; contact local poison control or toxicology services per facility protocol for overdose guidance
- If breastfeeding, report infant limpness, poor feeding, or unusual sleepiness to the care team immediately
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Significant respiratory depression, apnea, or SpO2 below protocol threshold
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, MAOI use within 14 days, or hypersensitivity to morphine
- Excessive sedation or patient unarousable
- Unclear mg versus mL order, wrong vial concentration, or independent double-check mismatch
- New concurrent CNS depressant without a revised safe opioid plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Morphine remains a foundational inpatient analgesic, but its primary nursing failure mode is treating pain scores while missing declining ventilation—especially after IV boluses with delayed peak effect. Build respiratory assessment into every opioid pass and recovery handoff.
1. Check-before-you-give protocol
- Right patient, right drug, right mg dose, right mL, right concentration (mg/mL), right route, right time
- Independent double-check with second licensed clinician for bolus and infusion starts
- Confirm naloxone, airway equipment, and trained responder immediately available
- Baseline RR, SpO2, and sedation score documented before dose and per protocol after—including the 30-minute post-IV window
2. High-alert and safety badge
Schedule II high-alert opioid — multiple mg/mL concentrationsLabeling requires naloxone injection and resuscitative equipment immediately available when initiating morphine and warns that dosing errors from mg/mL and concentration confusion can cause accidental overdose and death.
3. Clinical workflow: hold and question rules
- If RR is declining or SpO2 falling after a dose, hold further morphine and escalate before repeating analgesia
- Handoff must include last morphine dose, concurrent sedatives, concentration used, and whether ventilation is stable
- Contact poison control or toxicology per facility protocol when overdose is suspected; maintain airway while awaiting guidance
4. Critical teach-back questions
- “What breathing changes should you report right away while receiving morphine?” (Patient should name slow or shallow breathing, extreme sleepiness, or difficulty waking up.)
- “Why should you avoid extra sedatives or alcohol with morphine?” (Patient should understand combined drugs can stop breathing.)
5. Care coordination
Pharmacist: Consult for mg/mL verification, renal dosing, opioid rotation, and antagonist dosing when partial or recurrent reversal occurs
Prescriber: Notify for persistent respiratory depression, need for alternate analgesia, neonatal exposure concerns, or repeated naloxone doses
🧠 Quick mental checklist
- What is this patient’s respiratory rate, depth, SpO2, and arousability right now?
- What morphine and other opioids or sedatives have they received in the last 24 hours?
- Does the order match the vial concentration (mg/mL) and calculated mL volume?
- Are naloxone and airway support immediately available?
- If ventilation is declining, have I held morphine and activated escalation?
Morphine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for morphine sulfate using a tabbed postoperative case (MAR, labs, vitals, nursing notes), then rotate priority action, respiratory cue recognition, deterioration trends, matrix urgency sorting, antagonist management, and antidote cloze—recognise cues → analyse → prioritise → act → evaluate outcomes tied to respiratory depression and concentration safety.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Morphine sulfate 4 mg IV q4h PRN moderate pain — 4 mg given at 1400 (4 mg/mL — 1 mL)
- Lorazepam 0.5 mg IV q6h PRN anxiety — 0.5 mg at 1330
- Morphine sulfate 4 mg IV PRN due 1800; pharmacy label on cart: 4 mg/mL and 10 mg/mL vials stocked
- 1730: patient reports pain 7/10; no morphine documented since 1400 dose
- Admission BMP: creatinine 1.4 mg/dL (baseline 1.3)
- eGFR 52 mL/min/1.73 m2 — pharmacy note: active metabolite risk with morphine
- ABG not drawn; SpO2 monitoring per post-op protocol
- 1415 (15 min post 4 mg IV): RR 14, SpO2 96% on 2 L/min, easily arousable
- 1700: RR 10, SpO2 92% on 2 L/min, drowsy but oriented
- 1730: RR 8, SpO2 89% on 2 L/min, difficult to arouse with verbal stimulus
- 68-year-old post open cholecystectomy, day 0; history of COPD and home oxygen at night
- 1720: Patient drifting to sleep mid-sentence; roommate notes loud snoring
- 1730: Nurse preparing morphine 4 mg IV for pain 7/10; 10 mg/mL vial on bedside tray
- Naloxone and airway cart verified on unit per policy
Answer key & rationale
Frequently asked questions
What is the greatest nursing safety risk with morphine?
Serious, life-threatening, or fatal respiratory depression may occur with morphine sulfate injection, especially during initiation or after a dose increase. Because maximum CNS effect after IV morphine may be delayed about 30 minutes, rapid administration can overdose the patient. Concomitant benzodiazepines or other CNS depressants increase fatal respiratory depression risk.
What IV adult dosing does morphine sulfate injection labeling describe?
For adults, reviewed morphine sulfate injection labeling initiates treatment in a dosing range of 0.1 mg to 0.2 mg per kg every 4 hours as needed to manage pain and instructs that the injection be administered slowly. Oral and extended-release products have separate prescribing information.
What antidote is used for morphine respiratory depression?
Opioid antagonists such as naloxone are specific antidotes to respiratory depression resulting from morphine overdose per reviewed prescribing information. Continue monitoring and repeat antagonist doses as directed because reversal duration may be shorter than morphine action. Contact local poison control or medical toxicology services per facility protocol.
When should a nurse hold morphine and contact the prescriber or pharmacist?
Hold for significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, gastrointestinal obstruction, MAOI use within 14 days, hypersensitivity, excessive sedation or apnea, unclear mg versus mL orders, wrong vial concentration, or new CNS depressants without a safe concurrent plan.
Is morphine safe during breastfeeding?
Morphine is present in breast milk. Reviewed morphine sulfate injection labeling states there is insufficient information to determine effects on the breastfed infant or on milk production for that product. LactMed reports variable morphine concentrations after maternal immediate-release morphine; monitor breastfed infants for sedation and respiratory depression and discuss alternatives with the prescriber when concern exists.
References
-
DailyMed — Morphine Sulfate Injection (Hospira, Inc.), revised prescribing informationhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be420e8b-bcb0-49b5-bb4d-1df8b9959809
-
LactMed — Morphine (NIH/NLM drugs and lactation database)https://www.ncbi.nlm.nih.gov/books/NBK501668/
-
StatPearls / NCBI Bookshelf — Opioid analgesics (nursing-relevant pharmacology reference)https://www.ncbi.nlm.nih.gov/books/NBK501202/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.